SMSimone A. Minnie

Simone A. Minnie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simone A. Minnie has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IFN-γ–driven MHC class II on gut epithelium induces cytolytic T H 1 cell differentiation and stem cell loss in graft-versus-host disease

    by Motoko Koyama, Albert C. Yeh, Françoise Haeseleer, Kathleen S. Ensbey, Shruti S. Bhise, Iona S. Schuster, Samuel R. W. Legg, Ethan L. Nelson, Tomoko Sekiguchi, Nicole S. Nemychenkov, et al.

    The molecular cues by which CD4 T cells are invoked to mediate lethal gut graft-versus-host disease (GVHD) at the epithelial interface after allogeneic hematopoietic stem cell transplantation are unclear. Here, we demonstrate that MHC class II (MHCII) but not MHC class I expression by intestinal epithelial cells (IECs) within the first 3 days of transplantation promotes lethal GVHD in mice. This was dependent on direct IFN-γ–dependent induction of MHCII on IECs, which expanded perforin/granzyme B–expressing cytolytic donor T H 1 cell while restraining T H 17 cell differentiation locally within the ileum. In contrast, intestinal stem cells (ISCs) were preferentially and progressively depleted by cytolytic T H 1 cells as a result of IFN-γ–induced MHCII expression. Together, IEC-intrinsic IFN-γ signaling is critical for the MHCII-dependent early local generation of cytolytic T H 1 cells that thereafter mediate MHCII-dependent ISC deletion. These data demonstrate a critical IFN-γ–MHCII feed-forward axis in the initiation of cytolytic T H 1 cell–dependent gut disease.

  • Open Access

    CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation

    by Simone A. Minnie, Kenneth Ho, Julie R. Boiko, Rachael C. Adams, Kathleen S. Ensbey, Nicole S. Nemychenkov, Samuel R. W. Legg, Christine R. Schmidt, Melissa L. Comstock, Justina M. Lyons, et al.

    Autologous stem cell transplantation (ASCT) with maintenance lenalidomide remains the mainstay of consolidation therapy for eligible patients with multiple myeloma, but preventing disease relapse remains a critical unmet need. Here, we investigated whether immunosuppressive myeloid populations in bone marrow correlated with ASCT outcomes. We identified a subset of CD64+CD169+CD163+ macrophages that expressed CSF-1R, PD-L1, and CD155 and were expanded in patients who relapsed after ASCT. Using a preclinical ASCT model with suboptimal endogenous antimyeloma activity, we demonstrated that although neither CSF-1R inhibition nor lenalidomide monotherapy significantly improved outcomes, their combination synergistically attenuated disease progression and prolonged survival. Single-cell RNA sequencing revealed that lenalidomide expanded natural killer (NK)–like CD8+ T cells but paradoxically also increased the frequency of Csf1r+ macrophages. Cell-cell communication analyses identified Csf1r+ macrophages as suppressors of these NK- and effector-like phenotypically exhausted (Tphex) CD8 T-cell populations through CD94/NKG2A and PD-L1/PD-1, respectively. CSF-1R blockade depleted these immunosuppressive macrophages, which correlated with decreased expression of inhibitory receptors and enhanced expression of activation markers in Tphex. Given the US Food and Drug Administration approval of axatilimab for chronic graft-versus-host disease, combining CSF-1R blockade with lenalidomide maintenance represents a readily testable strategy to improve progression-free survival after ASCT.


  • Open Access

    Targeting donor XCR1+ and CD11b+ dendritic cells prevents Th1 and Th17-dependent GVHD within the Gastrointestinal Tract.

    by Shuichiro Takahashi, Takayuki Inoue, Kathleen S. Ensbey, Samuel Rw Legg, Tomoko Sekiguchi, Ethan L Nelson, Nicole S Nemychenkov, Tanvi Joshi, Simone Minnie, Albert C Yeh, et al.

    Acute graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract is a primary cause of early transplant mortality after bone marrow transplantation (BMT), driven by local antigen presentation and T-cell expansion. We sought to clarify the role of various donor dendritic cell (DC) subsets in this process in order to define therapeutic strategies to prevent gut GVHD. Donor plasmacytoid DC (pDC) were prominent in the ileum of BMT recipients without GVHD but were largely absent in gut during GVHD. In contrast, donor XCR1+ conventional DC (cDC) were dramatically increased in the mesenteric lymph nodes (mLN) of BMT recipients with GVHD. We utilized Xcr1-DTR mice and Clec4c-DTR mice to enable highly efficient XCR1+ cDC versus pDC depletion. Donor XCR1+ cDC but not pDC deletion attenuated lethal GVHD, depleting most cDC presenting alloantigen, which inhibited α4β7 and the expansion of alloantigen-specific donor Th1 cells in the gut. Aldehyde dehydrogenase 1A (ALDH1A) expression by cDC is known to modulate GVHD and we thus examined the effect of a pan-ALDH1 inhibitor, WIN18,446, on this axis. WIN18,446 administration improved survival and these effects were ALDH1A1-specific but mediated by inhibition of CD11b+ rather than XCR1+ cDC, inhibiting alloantigen-specific Th17 cell differentiation in the gut. These findings highlight the limited role of pDC in the induction of gut GVHD and identify differential and dominant roles for XCR1+ and CD11b+ donor cDC in controlling Th1 and Th17 mediated gut aGVHD. The targeting of donor cDC subsets represents an effective strategy to prevent lethal gut GVHD.


  • Open Access

    Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD. Reply.

    by Ping Zhang, Simone A. Minnie, Geoffrey R. Hill

    Senjo et al. recently transplanted equal and high numbers of congenic CD8 + 2C T cell receptor-transgenic (CD8 + 2C TCR-Tg) and polyclonal B6 (CD4 + and CD8 +) T cells into lethally irradiated B6D2F1 mice and determined T cell differentiation in the presence/absence of cyclosporin, dosed orally at 25 mg/kg/day for 14 days (1). Absorption was not validated by drug levels. Interpretation was heavily influenced by single-cell RNA-seq (scRNA-seq) analyses on day 14 with subsequent protein analyses, performed principally on CD8 + 2C TCR-Tg T cells. In contrast, our findings were primarily in alloreactive CD4 + T cells, with validation of expansion kinetics using small numbers of H-Yspecific CD4 + TCR-Tg T cells (2). We noted preferential CD4 + central memory T cell (Tcm) generation in both polyclonal and HY-TCR-Tg T cells in the presence of a calcineurin inhibitor (CNI) and importantly, this expansion was dose and agent (tacrolimus > cyclosporin) dependent (2). Senjo et al. concluded from their scRNA-seq data that cyclosporin promoted the expansion of transitory-exhausted (transitory-Tex) CD8 + T cells based on reduced PD-1, TIGIT, and TOX, and increased CX3CR1 RNA expression relative to other T cell clusters. We note that the population expanded by cyclosporin in cluster C1 contains a large fraction of TOX-cells, as acknowledged by Senjo et al. in their recent Letter to the Editor (3). Consistent with this, the protein data in Senjo et al. (Figure 3F) (1) demonstrate that approximately 50% of 2C TCR-Tg T cells are TOX-with cyclosporin. They did not analyze memory or exhausted T cell subsets by flow cytometry. Of note, CX3CR1 expression is consistent with effector/memory T cells and does not delineate transitory-Tex in the absence of TOX expression (4). Senjo et al. assert that Ly6C specifically marks transitory-Tex based on scRNA-seq data (Figure 1E and ref. 3). Ly6C is broadly expressed on memory CD8 + T cells (5) and is most highly expressed on antigen-induced Tcm subsets (6). Indeed, Figure 3I of the Senjo et al. paper (1) shows that 64% of T cells expressed Ly6C in the presence of a CNI, but a large fraction of Ly6C + cells appear TOX-. Thus, Ly6C does not discriminate transitory-Tex cells from other CD8 + T cell subsets after bone marrow transplantation (BMT) with a CNI and in fact, Ly6C + CD8 + T cells are enriched for nonexhausted (TOX-) T cells (Figure 1). Thus, the flow cytometry data in Figure 3, F and I of Senjo et al. and our own align. Critically, Senjo et al. note that they transferred Ly6C + T cells (including CD4 + T cells), which gave rise to chronic GVHD (cGVHD) and the generation of TOX + exhausted and TOX-effectors. The latter confirms that these cells are not a pure population of transitory-Tex, given that this population is irreversibly committed to exhaustion (i.e., should not generate TOX-effector T cells; ref. 7). Conversely, we transferred purified populations of CNI-induced CD4 + Tcm, which preferentially generated cGVHD. We acknowledge that most of our analyses were on day 7 or 17 after BMT, the latter 4 days after withdrawal of the CNI. Nevertheless, we undertook analyses at the same day 14 time point (Figure 6 and ref. 2) in the same model (but without 2C TCR-Tg T cells)


  • Open Access

    Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD

    by Yewei Wang, Ashik Ullah, Olivia G. Waltner, Shruti S. Bhise, Kathleen S. Ensbey, Christine R. Schmidt, Samuel R.W. Legg, Tomoko Sekiguchi, Ethan L. Nelson, Rachel D. Kuns, et al.

    Calcineurin inhibitors (CNIs) constitute the backbone of modern acute graft-versus-host disease (aGVHD) prophylaxis regimens but have limited efficacy in the prevention and treatment of chronic GVHD (cGVHD). We investigated the effect of CNIs on immune tolerance after stem cell transplantation with discovery-based single-cell gene expression and T cell receptor (TCR) assays of clonal immunity in tandem with traditional protein-based approaches and preclinical modeling. While cyclosporin and tacrolimus suppressed the clonal expansion of CD8 + T cells during GVHD, alloreactive CD4 + T cell clusters were preferentially expanded. Moreover, CNIs mediated reversible dose-dependent suppression of T cell activation and all stages of donor T cell exhaustion. Critically, CNIs promoted the expansion of both polyclonal and TCR-specific alloreactive central memory CD4 + T cells (T CM ) with high self-renewal capacity that mediated cGVHD following drug withdrawal. In contrast to posttransplant cyclophosphamide (PT-Cy), CSA was ineffective in eliminating IL-17A–secreting alloreactive T cell clones that play an important role in the pathogenesis of cGVHD. Collectively, we have shown that, although CNIs attenuate aGVHD, they paradoxically rescue alloantigen-specific T CM , especially within the CD4 + compartment in lymphoid and GVHD target tissues, thus predisposing patients to cGVHD. These data provide further evidence to caution against CNI-based immune suppression without concurrent approaches that eliminate alloreactive T cell clones.


  • TIM-3 + CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies

    by Simone A. Minnie, Olivia G. Waltner, Ping Zhang, Shuichiro Takahashi, Nicole S. Nemychenkov, Kathleen S. Ensbey, Christine R. Schmidt, Samuel R. W. Legg, Melissa Comstock, Julie R. Boiko, et al.

    Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a CD8 T cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (T PHEX ), expressed granzymes, perforin, and IFN-γ. Concurrent gene expression and DNA accessibility revealed that genes encoding these functional proteins correlated with BATF expression and motif accessibility. IFN-γ + T PHEX effectively killed myeloma with comparable efficacy to transitory effectors, and disease progression correlated with numerical deficits in IFN-γ + T PHEX . We also observed IFN-γ + T PHEX within CD19-targeted chimeric antigen receptor T cells, which killed CD19 + leukemia cells. An IFN-γ + T PHEX gene signature was recapitulated in T EX cells from human cancers, including myeloma and lymphoma. Here, we characterize a T EX subset in hematological malignancies that paradoxically retains function and is distinct from dysfunctional T EX found in chronic viral infections. Thus, IFN-γ + T PHEX represent a potential target for immunotherapy of blood cancers.


  • Open Access

    IL-6–mediated endothelial injury impairs antiviral humoral immunity after bone marrow transplantation

    by Ping Zhang, Peter Fleming, Christopher E. Andoniou, Olivia G. Waltner, Shruti S. Bhise, Jose Paulo Martins, Benjamin A. McEnroe, Valentina Voigt, Sheridan Daly, Rachel D. Kuns, et al.

    Endothelial function and integrity are compromised after allogeneic bone marrow transplantation (BMT), but how this affects immune responses broadly remains unknown. Using a preclinical model of CMV reactivation after BMT, we found compromised antiviral humoral responses induced by IL-6 signaling. IL-6 signaling in T cells maintained Th1 cells, resulting in sustained IFN-γ secretion, which promoted endothelial cell (EC) injury, loss of the neonatal Fc receptor (FcRn) responsible for IgG recycling, and rapid IgG loss. T cell–specific deletion of IL-6R led to persistence of recipient-derived, CMV-specific IgG and inhibited CMV reactivation. Deletion of IFN-γ in donor T cells also eliminated EC injury and FcRn loss. In a phase III clinical trial, blockade of IL-6R with tocilizumab promoted CMV-specific IgG persistence and significantly attenuated early HCMV reactivation. In sum, IL-6 invoked IFN-γ–dependent EC injury and consequent IgG loss, leading to CMV reactivation. Hence, cytokine inhibition represents a logical strategy to prevent endothelial injury, thereby preserving humoral immunity after immunotherapy.


  • Intestinal microbiota controls graft-versus-host disease independent of donor-host genetic disparity

    by Motoko Koyama, Daniel S. Hippe, Sujatha Srinivasan, Sean C. Proll, Oriana Miltiadous, Naisi Li, Ping Zhang, Kathleen S. Ensbey, Noah G. Hoffman, Christine R. Schmidt, et al.


  • Open Access

    TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice

    by Simone A. Minnie, Olivia G. Waltner, Kathleen S. Ensbey, Stuart D. Olver, Alika D. Collinge, David P. Sester, Christine R. Schmidt, Samuel R.W. Legg, Shuichiro Takahashi, Nicole S. Nemychenkov, et al.

    Autologous stem cell transplantation (ASCT) with subsequent lenalidomide maintenance is standard consolidation therapy for multiple myeloma, and a subset of patients achieve durable progression-free survival that is suggestive of long-term immune control. Nonetheless, most patients ultimately relapse, suggesting immune escape. TIGIT appears to be a potent inhibitor of myeloma-specific immunity and represents a promising new checkpoint target. Here we demonstrate high expression of TIGIT on activated CD8+ T cells in mobilized peripheral blood stem cell grafts from patients with myeloma. To guide clinical application of TIGIT inhibition, we evaluated identical anti-TIGIT antibodies that do or do not engage FcγR and demonstrated that anti-TIGIT activity is dependent on FcγR binding. We subsequently used CRBN mice to investigate the efficacy of anti-TIGIT in combination with lenalidomide maintenance after transplantation. Notably, the combination of anti-TIGIT with lenalidomide provided synergistic, CD8+ T cell–dependent, antimyeloma efficacy. Analysis of bone marrow (BM) CD8+ T cells demonstrated that combination therapy suppressed T cell exhaustion, enhanced effector function, and expanded central memory subsets. Importantly, these immune phenotypes were specific to the BM tumor microenvironment. Collectively, these data provide a logical rationale for combining TIGIT inhibition with immunomodulatory drugs to prevent myeloma progression after ASCT.


  • Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity

    by Simone A. Minnie, Olivia G. Waltner, Kathleen S. Ensbey, Nicole S. Nemychenkov, Christine R. Schmidt, Shruti S. Bhise, Samuel R. W. Legg, Gabriela Campoy, Luke D. Samson, Rachel D. Kuns, et al.

    Some hematological malignancies such as multiple myeloma are inherently resistant to immune-mediated antitumor responses, the cause of which remains unknown. Allogeneic bone marrow transplantation (alloBMT) is the only curative immunotherapy for hematological malignancies due to profound graft-versus-tumor (GVT) effects, but relapse remains the major cause of death. We developed murine models of alloBMT where the hematological malignancy is either sensitive [acute myeloid leukemia (AML)] or resistant (myeloma) to GVT effects. We found that CD8 + T cell exhaustion in bone marrow was primarily alloantigen-driven, with expression of inhibitory ligands present on myeloma but not AML. Because of this tumor-independent exhaustion signature, immune checkpoint inhibition (ICI) in myeloma exacerbated graft-versus-host disease (GVHD) without promoting GVT effects. Administration of post-transplant cyclophosphamide (PT-Cy) depleted donor T cells with an exhausted phenotype and spared T cells displaying a stem-like memory phenotype with chromatin accessibility present in cytokine signaling genes, including the interleukin-18 (IL-18) receptor. Whereas ICI with anti–PD-1 or anti–TIM-3 remained ineffective after PT-Cy, administration of a decoy-resistant IL-18 (DR-18) strongly enhanced GVT effects in both myeloma and leukemia models, without exacerbation of GVHD. We thus defined mechanisms of resistance to T cell–mediated antitumor effects after alloBMT and described an immunotherapy approach targeting stem-like memory T cells to enhance antitumor immunity.